What Aprotinin Treats: Main Uses and Benefits

Aprotinin is a specialized therapeutic agent intended to support the patient in specific, high-risk surgical situations. The main benefit is to aid in the management of blood loss during certain complex procedures, most notably coronary artery bypass graft (CABG) surgery that involves cardiopulmonary bypass. By supporting the body's processes in this context, the agent helps physicians to reduce the potential need for blood transfusions during and immediately following the operation.

This agent serves as a supportive measure in major cardiovascular operations to address clinical concerns related to excessive fibrinolysis (clot breakdown). It is considered a tool for specialized teams managing these procedures, rather than a treatment for general, non-surgical conditions.

Quick Fact: Relief for Managing Blood Loss

Who Can and Cannot Use Aprotinin

The eligibility to receive Aprotinin is strictly regulated, focusing on specific adult populations and excluding patients with contraindications defined by regulatory authorities.

Contraindicated Populations

Official labeling mandates that Aprotinin must not be used in the following populations:

Classification	Population Restriction
Absolute Contraindication	Patients with a known history of hypersensitivity (allergic reaction) to Aprotinin.
Absolute Contraindication	Patients with a history of prior exposure to Aprotinin within the previous 12 months, due to the high risk of a severe allergic reaction.

Eligibility and Age Restrictions

Aprotinin is approved for use only in adult patients undergoing high-risk Coronary Artery Bypass Graft (CABG) surgery with cardiopulmonary bypass. The safety and effectiveness of the medicine have not been established in the pediatric population (patients under 18 years of age), making them generally ineligible for use.

Other Population Restrictions

• Pregnancy and Lactation: Use is not recommended during pregnancy or for breastfeeding mothers due to insufficient safety data.
• Prior Exposure: If a patient was exposed to Aprotinin more than 12 months ago, use is conditional and requires a mandatory test dose prior to administration to check for sensitivity.

Aprotinin's official interaction profile is defined by regulatory restrictions and specific pharmacodynamic patterns relevant to its use in acute settings. The most critical restriction is the formal contraindication against re-exposure to Aprotinin-containing products. Prior administration of the drug significantly increases the risk of severe hypersensitivity, including anaphylaxis, especially if the subsequent dose is given within six months.

Pharmacodynamic interactions are documented with agents affecting clot formation. Co-administration with fibrinolytic agents (thrombolytics) such as Alteplase or Urokinase may result in the inhibition of their therapeutic effect due to Aprotinin’s antifibrinolytic activity. Additionally, the drug has been observed to block the acute hypotensive effect of the ACE inhibitor Captopril in relevant studies.

A critical procedural interaction involves Heparin. Aprotinin prolongs the Activated Clotting Time (ACT) measurement, particularly when a celite activation method is used, requiring specific monitoring considerations. Due to physical incompatibility, the regulatory label mandates that Aprotinin and Heparin must be added separately and diluted into the pump prime. Furthermore, Aprotinin is incompatible with several classes of antibiotics (including Tetracyclines) and certain corticosteroids, meaning no other drug should be administered through the same central line used for the infusion. Regulatory documents do not report significant interactions with CYP enzymes, food, alcohol, or herbal products.

Stabilizing Blood Clots Through Anti-Fibrinolysis

This mechanism centers on the rapid, competitive inhibition of the enzyme Plasmin, the primary biological target responsible for the proteolytic dissolution of fibrin clots. By binding to Plasmin, the drug immediately prevents the enzymatic degradation of the fibrin matrix, leading to enhanced fibrin clot persistence and resulting in a stabilizing effect on the hemostatic system.

---

Modulating the Inflammatory Cascade via Kallikrein

Aprotinin acts by inhibiting Plasma Kallikrein, a key enzyme in the Contact Activation System. This action dampens the initiation of a major inflammatory cascade, reducing the formation of mediators like Bradykinin and attenuating the systemic inflammatory response. This modulation results in the dampening of pathway activation within cascades that can escalate under acute systemic stress.

---

Preservation of Platelet Function

The drug’s anti-fibrinolytic action results in the functional preservation of blood components. By preventing Plasmin activity, Aprotinin maintains the integrity of surface glycoproteins on platelets. This mechanism ensures that platelets retain their full functional capacity for adhesion and aggregation, contributing to hemostatic modulation in the microvasculature.

Administration Guidelines for Aprotinin

Aprotinin is administered strictly by intravenous (IV) injection or continuous infusion via a central venous catheter in a clinical setting. Its use is reserved for adult patients at high risk of major blood loss undergoing isolated coronary artery bypass graft surgery (iCABG). Use in the paediatric population has not been established.

Dosing Protocol (The Hamburg Regimen)

The official administration follows a specific, multi-step regimen during the perioperative period, and the total dose per treatment course should generally not exceed 7 million KIU.

Procedural Step	Dose (Kallikrein Inactivator Units—KIU)	Timing and Administration
Test Dose	10,000 KIU (1 ml)	Administered 10 minutes before the loading dose.
Loading Dose	1 - 2 million KIU	Slow IV injection/infusion over 20 - 30 minutes after anaesthesia induction, prior to sternotomy.
Pump Prime Dose	1 - 2 million KIU	Added to the pump prime of the heart-lung machine.
Continuous Infusion	250,000 - 500,000 KIU/hour	Maintained until the end of the operation.

Preparation and Procedural Rules

Administration must only occur with the patient in the supine position and given slowly (maximum 5–10 ml/min). Aprotinin is supplied ready for infusion. When preparing the pump prime solution, a specific procedural step is required to avoid physical incompatibility with heparin: each agent must be added during recirculation of the pump prime to ensure adequate dilution before being mixed. The central catheter lumen used for Aprotinin must not be used for any other medicinal product.

Research Evidence / Overview of Studies for Апротинин

This overview describes the scope of the clinical research and the types of studies that have examined Aprotinin. It focuses only on the official evidence base relied upon by regulators and major scientific review bodies. This section provides context about the available research and does not include clinical advice, safety warnings, or dosing instructions.

Evidence for Use in High-Risk Cardiac Surgery

The research foundation primarily consists of Randomized Controlled Trials (RCTs), a study design used to examine acute effects and compare outcomes between groups. These trials have been combined and analyzed in large Systematic Reviews and Meta-analyses. The entire body of research was studied for its use during specific, major cardiac operations, such as isolated coronary artery bypass graft (iCABG) surgery, in adult patients who appear to be at an increased risk for excessive bleeding.

Studies conducted in these surgical settings explored the association between Aprotinin and patterns related to blood management. Findings describe patterns observed in the studies related to measured clinical outcomes following the procedure. The evidence also includes large-scale Observational Studies and follow-up programs used to monitor patterns in specific care settings.

Study Focus: Blood Loss and Transfusion Requirements

Research examined endpoints related to the management of blood in patients. The studies primarily monitored and measured endpoints such as the volume of perioperative blood loss and the rate and volume of allogeneic red blood cell transfusion administered in patients. Researchers also evaluated the incidence of reoperation due to bleeding—an outcome reflecting episodic or acute changes. Across many of the RCTs reviewed by regulators, research highlights patterns of measurements recorded during the study period, including differences in these outcomes when compared to control groups.

Areas of Research Uncertainty and Study Limitations

Several factors limit the certainty of the overall evidence, which must be considered when reviewing the findings: A key limitation is that many earlier RCTs had sample sizes that were modest and follow-up durations were limited. This meant that the studies lacked the statistical power required to reliably assess the incidence of rare, serious clinical events. Research does not determine whether an individual will respond similarly when these events are rare. Furthermore, certainty remains low for some of the comparisons, and the reliance on large Observational Studies (a study type that presents challenges for controlling variables) introduces uncertainty into some of the reported patterns. These studies help show what has been observed so far, but the evidence highlights what is known and what is still uncertain regarding outcomes outside of primary endpoints.

Common questions about Апротинин (FAQ)

---

Q: How quickly does the effect of Апротинин start?

A: According to the official product information, the drug begins acting immediately upon administration, as it is delivered directly into the bloodstream. Aprotinin is cleared from the body in two phases, starting with a rapid distribution half-life of about 5 to 10 minutes.

---

Q: Is it true that Апротинин was taken off the market at one point?

A: Yes, regulatory bodies, including the FDA and the European Medicines Agency, temporarily suspended the use of Aprotinin in 2007. Following a comprehensive review of clinical trial data, regulators later lifted the suspension, allowing its restricted use for specific, high-risk cardiac procedures.

---

Q: What is the official safety classification of Апротинин?

A: Aprotinin is categorized by regulatory bodies as an Antifibrinolytic Agent and a Proteinase Inhibitor. This classification describes its primary action, which is to inhibit the breakdown of fibrin clots. Its official international classification code (ATC) is B02AB01.

---

Q: How does Апротинин compare to other agents used for minimizing blood loss in surgery?

A: Regulatory reviews indicate that the use of Aprotinin requires careful consideration of its potential benefits and risks relative to alternatives in the specific context of high-risk surgery. Official regulatory bodies have compared Aprotinin against other antifibrinolytic agents regarding blood loss reduction and safety outcomes.

---

Q: How long does the drug stay in the body after an operation?

A: Official pharmacological data indicate that after the initial rapid phase, the terminal elimination half-life of Aprotinin is approximately 10 hours. This means it takes about that long for the amount of drug in the body to be reduced by half. A portion of the drug is then cleared from the body through the urine over the two days following the procedure.

---

Q: Is there a generic version of Апротинин available?

A: Yes, the active ingredient Aprotinin has been made available as both a branded product and as a generic medicine in some regulated markets. Availability and specific product names can vary based on national regulatory approval.

---

Q: If I have a history of a specific heart condition, can I still receive Апротинин?

A: The drug is restricted to use in patients undergoing isolated Coronary Artery Bypass Graft (CABG) surgery. Official warnings state that Aprotinin is contraindicated (officially prohibited) if the CABG surgery is combined with other types of heart procedures, as the appropriate benefit-risk balance has not been established for those situations.

---

Q: What are the criteria for discontinuing the use of Апротинин during surgery?

A: According to regulatory warnings and precautions, the administration of Aprotinin must be stopped immediately if the patient shows signs of a hypersensitivity reaction (a severe allergic reaction) during the injection or infusion.

---

Storage and Disposal of Aprotinin

Official regulatory documents specify mandatory conditions to ensure the quality and stability of Aprotinin. The unopened solution must be stored at controlled temperatures, generally ranging from mathbf2^° C to mathbf25^° C (mathbf36^° F to mathbf77^° F). It is a strict requirement to protect the product from freezing.

To prevent degradation from light, Aprotinin must be kept in its original package.

Stability and Handling

Once the solution is diluted for administration, its chemical stability is typically limited to 6 hours at mathbf25^° C. From a microbiological viewpoint, the diluted solution should be used immediately. The product must be stored out of the sight and reach of children.

Discarding Unused Product

Regulators explicitly instruct that unused or expired Aprotinin must not be thrown away via household waste or wastewater. Disposal must follow local guidelines; consult a pharmacist for the proper procedure to discard medicines you no longer use.